Search
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Jean-Luc Herbeaux to become Hovione CEO
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Hovione honored with the Leonardo da Vinci Prize 2025
Presented by the Hénokiens Association and the Château du Clos Lucé
World Patient Safety Day 2021
Safety First, Quality Always: We are continuously improving the safety of our operations with the patient’s safety in mind.
Hovione Unveils New Continuous Tableting Line at Lisbon R&D Centre
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.
Hovione and Zerion Pharma announce a strategic partnership to market the Dispersome® technology platform
Hovione, the leader in spray drying and particle engineering, announced today a strategic partnership with Zerion Pharma to market and commercialize Dispersome®, Zerion´s proprietary solubility enhancement technology platform.